Amylyx Pharmaceuticals, Inc. Operating Income
Amylyx Pharmaceuticals, Inc. (AMLX) reported Operating Income of -$45.69 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-06
- Amylyx Pharmaceuticals, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$45.69M.
- Amylyx Pharmaceuticals, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$43.78M.
- Amylyx Pharmaceuticals, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$36.60M.
- Amylyx Pharmaceuticals, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$36.03M.
- Amylyx Pharmaceuticals, Inc. operating income (loss) for fiscal 2025 was -$153.29M.
- Amylyx Pharmaceuticals, Inc. operating income (loss) for fiscal 2024 was -$314.73M, a 911.12% decline from fiscal 2023.
- Amylyx Pharmaceuticals, Inc. operating income (loss) for fiscal 2023 was $38.80M.
- Amylyx Pharmaceuticals, Inc. operating income (loss) for fiscal 2022 was -$201.34M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$45.69M 10-Q · filed 2026-08-06 | -$89.47M 10-Q · filed 2026-08-06 | -$126.08M derived: sum of 3 quarters · filed 2026-08-06 | -$162.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$43.78M 10-Q · filed 2026-05-07 | -$80.38M derived: sum of 2 quarters · filed 2026-05-07 | -$116.41M derived: sum of 3 quarters · filed 2026-05-07 | -$159.27M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$36.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$72.63M derived: sum of 2 quarters · filed 2026-03-03 | -$115.49M derived: sum of 3 quarters · filed 2026-08-06 | -$153.29M 10-K · filed 2026-03-03 |
| 2025-09-30 | -$36.03M 10-Q · filed 2025-11-06 | -$78.88M derived: sum of 2 quarters · filed 2026-08-06 | -$116.69M 10-Q · filed 2025-11-06 | -$157.34M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$42.86M 10-Q · filed 2026-08-06 | -$80.66M 10-Q · filed 2026-08-06 | -$121.31M derived: sum of 3 quarters · filed 2026-08-06 | -$196.97M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$37.80M 10-Q · filed 2026-05-07 | -$78.46M derived: sum of 2 quarters · filed 2026-05-07 | -$154.12M derived: sum of 3 quarters · filed 2026-05-07 | -$230.40M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$40.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$116.31M derived: sum of 2 quarters · filed 2026-03-03 | -$192.60M derived: sum of 3 quarters · filed 2026-03-03 | -$314.73M 10-K · filed 2026-03-03 |
| 2024-09-30 | -$75.66M 10-Q · filed 2025-11-06 | -$151.95M derived: sum of 2 quarters · filed 2025-11-06 | -$274.08M 10-Q · filed 2025-11-06 | -$272.14M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$76.29M 10-Q · filed 2025-08-07 | -$198.42M 10-Q · filed 2025-08-07 | -$196.48M derived: sum of 3 quarters · filed 2025-08-07 | -$177.76M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$122.13M 10-Q · filed 2025-05-08 | -$120.20M derived: sum of 2 quarters · filed 2025-05-08 | -$101.48M derived: sum of 3 quarters · filed 2025-05-08 | -$81.28M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $1.93M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $20.65M derived: sum of 2 quarters · filed 2025-03-04 | $40.85M derived: sum of 3 quarters · filed 2025-03-04 | $38.80M 10-K · filed 2025-03-04 |
| 2023-09-30 | $18.72M 10-Q · filed 2024-11-07 | $38.92M derived: sum of 2 quarters · filed 2024-11-07 | $36.87M 10-Q · filed 2024-11-07 | -$7.72M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $20.20M 10-Q · filed 2024-08-08 | $18.15M 10-Q · filed 2024-08-08 | -$26.45M derived: sum of 3 quarters · filed 2024-08-08 | -$81.13M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$2.05M 10-Q · filed 2024-05-09 | -$46.65M derived: sum of 2 quarters · filed 2024-05-09 | -$101.33M derived: sum of 3 quarters · filed 2024-05-09 | -$155.58M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$44.59M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$99.27M derived: sum of 2 quarters · filed 2024-02-22 | -$153.53M derived: sum of 3 quarters · filed 2024-02-22 | -$201.34M 10-K · filed 2024-02-22 |
| 2022-09-30 | -$54.68M 10-Q · filed 2023-11-09 | -$108.93M derived: sum of 2 quarters · filed 2023-11-09 | -$156.75M 10-Q · filed 2023-11-09 | -$185.06M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | -$54.25M 10-Q · filed 2023-08-10 | -$102.07M 10-Q · filed 2023-08-10 | -$130.38M derived: sum of 3 quarters · filed 2024-02-22 | -$153.30M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | -$47.81M 10-Q · filed 2023-05-11 | -$76.13M derived: sum of 2 quarters · filed 2024-02-22 | -$99.05M derived: sum of 3 quarters · filed 2024-02-22 | -$117.63M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | -$28.32M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$51.23M derived: sum of 2 quarters · filed 2024-02-22 | -$69.82M derived: sum of 3 quarters · filed 2024-02-22 | -$82.69M 10-K · filed 2024-02-22 |
| 2021-09-30 | -$22.92M 10-Q · filed 2022-11-10 | -$41.51M derived: sum of 2 quarters · filed 2022-11-10 | -$54.37M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | -$18.59M 10-Q · filed 2022-08-11 | -$31.45M 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | -$12.87M 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |